NanoViricides is trading at $1.41, up 8.46%, alongside its October 20, 2026 announcement that NV-387 showed favorable safety and tolerability in a juvenile mouse-pup study.
- The company reported no treatment-related adverse findings at the highest tested dose; results could support pediatric clinical trials.
- The stock closed at $1.30 on October 19. The release did not explicitly link the study update to the share-price move, and no trading-volume information was provided.